Two drugs go after the RAS mutation, a cancer switch no one could grab
At the EORTC-NCI-AACR symposium in Barcelona, two teams reported results from drugs aimed at RAS, a gene mutation that acts like a switch stuck in the "on" position. Until recently, designing a drug that could grip it was not thought possible.
In the AURORAS-1 phase I trial of ERAS-0015, a "pan-RAS molecular glue," 148 patients were enrolled, and the response figures covered 83 with pancreatic cancer and 37 with lung cancer who had already tried other treatments. Tumors shrank considerably in 44% of the pancreatic patients and 60% of the lung patients, with few severe side effects 34. In the second trial, 61 people with metastatic pancreatic cancer who had not yet been treated got daraxonrasib plus chemotherapy. Tumors shrank or disappeared in 60.7%, and 8.2% had no detectable tumor. Tumors stopped growing in 90.2%, and the median time before they returned was 12.8 months 45.